In a report released yesterday, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Compugen (CGEN – Research Report), with a price target of $4.00. The company’s shares closed yesterday at $1.74.
According to TipRanks, Willey is a 4-star analyst with an average return of 8.6% and a 42.56% success rate. Willey covers the Healthcare sector, focusing on stocks such as Exelixis, MEI Pharma, and IGM Biosciences.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Compugen with a $5.50 average price target, implying a 216.09% upside from current levels. In a report released on December 19, Leerink Partners also maintained a Buy rating on the stock with a $7.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $2.46 and a one-year low of $0.53. Currently, Compugen has an average volume of 2.19M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Compugen (CGEN) Company Description:
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.
Read More on CGEN:
- Compugen spikes after deal with Gilead for anti-tumor drug
- Compugen spikes 180% on $848M deal with Gilead for anti-tumor drug
- Compugen eligible to receive $10M payment upon dosing of AstraZeneca trial
- Gilead and Compugen in license deal for novel pre-clinical immunotherapy program
- Compugen reports Q3 EPS (11c), consensus (9c)
